[Angiotensin-2 type 1 receptors (AT1R) and cancers]. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Néphrologie & Thérapeutique Year : 2013

[Angiotensin-2 type 1 receptors (AT1R) and cancers].


Recently, several meta-analysis suggested an increased risk of cancers linked to the use of antagonists of angiotensin-2 receptors or inhibitors of angiotensinogen converting enzyme. The results of epidemiological studies are conflicting. Meta-analysis as well as retrospective studies are not reliable and biased, since they have never been designed to explore any pro- or antitumoral effect. We lack of prospective studies that could take off the doubt on these drugs. Nevertheless, all experimental researches pointed out potent antitumoral properties. Indeed, direct antiproliferative and neo-angiogenic inhibition have been described on tumor cell cultures as well as on animal models. Moreover, we are convinced that the use of antagonists of angiotensin-2 receptors and inhibitors of angiotensinogen converting enzyme may be then of clinical use in the near future in association with classical antitumor drugs. In this review, we proposed to explore these data by a thorough analysis of recent literature associating epidemiological and experimental studies.

Dates and versions

inserm-00814037 , version 1 (16-04-2013)



Thibault Dolley-Hitze, Grégory Verhoest, Florence Jouan, Patrick Le Pogamp, Yannick Arlot-Bonnemains, et al.. [Angiotensin-2 type 1 receptors (AT1R) and cancers].. Néphrologie & Thérapeutique, 2013, 9 (2), pp.85-91. ⟨10.1016/j.nephro.2012.09.006⟩. ⟨inserm-00814037⟩
260 View
0 Download



Gmail Facebook X LinkedIn More